Relevant bibliographies by topics / Vaccinia virus

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Vaccinia virus'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccinia virus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Vaccinia virus"

1

Tartaglia, James, and Enzo Paoletti. "Recombinant vaccinia virus vaccines." Trends in Biotechnology 6, no. 2 (February 1988): 43–46. http://dx.doi.org/10.1016/0167-7799(88)90035-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Doria-Rose, N. A., C. Ohlen, P. Polacino, C. C. Pierce, M. T. Hensel, L. Kuller, T. Mulvania, et al. "Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge." Journal of Virology 77, no. 21 (November 1, 2003): 11563–77. http://dx.doi.org/10.1128/jvi.77.21.11563-11577.2003.

Full text
Abstract:
ABSTRACT We evaluated four priming-boosting vaccine regimens for the highly pathogenic simian human immunodeficiency virus SHIV89.6P in Macaca nemestrina. Each regimen included gene gun delivery of a DNA vaccine expressing all SHIV89.6 genes plus Env gp160 of SHIV89.6P. Additional components were two recombinant vaccinia viruses, expressing SHIV89.6 Gag-Pol or Env gp160, and inactivated SHIV89.6 virus. We compared (i) DNA priming/DNA boosting, (ii) DNA priming/inactivated virus boosting, (iii) DNA priming/vaccinia virus boosting, and (iv) vaccinia virus priming/DNA boosting versus sham vaccines in groups of 6 macaques. Prechallenge antibody responses to Env and Gag were strongest in the groups that received vaccinia virus priming or boosting. Cellular immunity to SHIV89.6 peptides was measured by enzyme-linked immunospot assay; strong responses to Gag and Env were found in 9 of 12 vaccinia virus vaccinees and 1 of 6 DNA-primed/inactivated-virus-boosted animals. Vaccinated macaques were challenged intrarectally with 50 50% animal infectious doses of SHIV89.6P 3 weeks after the last immunization. All animals became infected. Five of six DNA-vaccinated and 5 of 6 DNA-primed/particle-boosted animals, as well as all 6 controls, experienced severe CD4+-T-cell loss in the first 3 weeks after infection. In contrast, DNA priming/vaccinia virus boosting and vaccinia virus priming/DNA boosting vaccines both protected animals from disease: 11 of 12 macaques had no loss of CD4+ T cells or moderate declines. Virus loads in plasma at the set point were significantly lower in vaccinia virus-primed/DNA-boosted animals versus controls (P = 0.03). We conclude that multigene vaccines delivered by a combination of vaccinia virus and gene gun-delivered DNA were effective against SHIV89.6P viral challenge in M. nemestrina.
APA, Harvard, Vancouver, ISO, and other styles
3

KUTINOVA, L. "Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them." Vaccine 13, no. 5 (1995): 487–93. http://dx.doi.org/10.1016/0264-410x(94)00019-j.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Precopio, Melissa L., Michael R. Betts, Janie Parrino, David A. Price, Emma Gostick, David R. Ambrozak, Tedi E. Asher, et al. "Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses." Journal of Experimental Medicine 204, no. 6 (May 29, 2007): 1405–16. http://dx.doi.org/10.1084/jem.20062363.

Full text
Abstract:
Vaccinia virus immunization provides lifelong protection against smallpox, but the mechanisms of this exquisite protection are unknown. We used polychromatic flow cytometry to characterize the functional and phenotypic profile of CD8+ T cells induced by vaccinia virus immunization in a comparative vaccine trial of modified vaccinia virus Ankara (MVA) versus Dryvax immunization in which protection was assessed against subsequent Dryvax challenge. Vaccinia virus–specific CD8+ T cells induced by both MVA and Dryvax were highly polyfunctional; they degranulated and produced interferon γ, interleukin 2, macrophage inflammatory protein 1β, and tumor necrosis factor α after antigenic stimulation. Responding CD8+ T cells exhibited an unusual phenotype (CD45RO−CD27intermediate). The unique phenotype and high degree of polyfunctionality induced by vaccinia virus also extended to inserted HIV gene products of recombinant NYVAC. This quality of the CD8+ T cell response may be at least partially responsible for the profound efficacy of these vaccines in protection against smallpox and serves as a benchmark against which other vaccines can be evaluated.
APA, Harvard, Vancouver, ISO, and other styles
5

Truong, Cao-Sang, and So Young Yoo. "Oncolytic Vaccinia Virus in Lung Cancer Vaccines." Vaccines 10, no. 2 (February 4, 2022): 240. http://dx.doi.org/10.3390/vaccines10020240.

Full text
Abstract:
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vaccines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.
APA, Harvard, Vancouver, ISO, and other styles
6

Jacobs, Bertram L., Jeffrey O. Langland, Karen V. Kibler, Karen L. Denzler, Stacy D. White, Susan A. Holechek, Shukmei Wong, Trung Huynh, and Carole R. Baskin. "Vaccinia virus vaccines: Past, present and future." Antiviral Research 84, no. 1 (October 2009): 1–13. http://dx.doi.org/10.1016/j.antiviral.2009.06.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Smith, Geoffrey L., Brendan J. Murphy, and Mansun Law. "Vaccinia Virus Motility." Annual Review of Microbiology 57, no. 1 (October 2003): 323–42. http://dx.doi.org/10.1146/annurev.micro.57.030502.091037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Perkus, M. E. "RECOMBINANT VACCINIA VIRUS." Pediatric Infectious Disease Journal 5, no. 2 (March 1986): 284. http://dx.doi.org/10.1097/00006454-198603000-00045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Broyles, Steven S. "Vaccinia virus transcription." Journal of General Virology 84, no. 9 (September 1, 2003): 2293–303. http://dx.doi.org/10.1099/vir.0.18942-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stittelaar, Koert J., Geert van Amerongen, Ivanela Kondova, Thijs Kuiken, Rob F. van Lavieren, Frank H. M. Pistoor, Hubert G. M. Niesters, et al. "Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus." Journal of Virology 79, no. 12 (June 15, 2005): 7845–51. http://dx.doi.org/10.1128/jvi.79.12.7845-7851.2005.

Full text
Abstract:
ABSTRACT The use of classical smallpox vaccines based on vaccinia virus (VV) is associated with severe complications in both naïve and immune individuals. Modified vaccinia virus Ankara (MVA), a highly attenuated replication-deficient strain of VV, has been proven to be safe in humans and immunocompromised animals, and its efficacy against smallpox is currently being addressed. Here we directly compare the efficacies of MVA alone and in combination with classical VV-based vaccines in a cynomolgus macaque monkeypox model. The MVA-based smallpox vaccine protected macaques against a lethal respiratory challenge with monkeypox virus and is therefore an important candidate for the protection of humans against smallpox.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Vaccinia virus"

1

Chan, Kenneth See Kit. "Nef from pathogenic simian immunodeficiency virus attenuates vaccinia virus /." For electronic version search Digital dissertations database. Restricted to UC campuses. Access is free to UC campus dissertations, 2004. http://uclibs.org/PID/11984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wallengren, Kristina. "Envelopment of retrovirus and vaccinia virus /." Stockholm, 2001. http://diss.kib.ki.se/2001/91-628-4851-8/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kettle, Susan. "Characterisation of vaccinia virus gene B13R." Thesis, University of Oxford, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.294390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moore, Jeffrey B. "Vaccinia virus 3[beta]-hydroxysteroid dehydrogenase." Thesis, University of Oxford, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359450.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Keller, Brian Andrew. "Functional Genomic Studies of Vaccinia Virus Provide Fundamental Insights into Virus-Host Interactions." Thesis, Université d'Ottawa / University of Ottawa, 2017. http://hdl.handle.net/10393/36614.

Full text
Abstract:
The oncolytic virus field is in the midst of strong and sustained growth. The clinical utility of this class of therapeutics has been bolstered in recent years by the rise of immune checkpoint inhibition, which has the potential to work synergistically with oncolytic viruses to increase the scope of patients who respond favourably to therapy. This growth has been further driven by clear industry support with several pharmaceutical companies acquiring or developing oncolytic virus products following the 2015 FDA approval of Talimogene laherparepvec and the generally-accepted potential of immunotherapeutic approaches to cancer treatment. Vaccinia virus is a double-stranded DNA virus with an extensive history of vaccine use in humans and a desirable safety profile. It is a large virus with a complex lifecycle, and its history of use as a vaccine has resulted in the generation of dozens of unique strains. Although it has been studied extensively, much remains unknown about many vaccinia virus gene function(s) and the virus’ interactions with cellular hosts. Vaccinia virus-based oncolytic viruses have been developed, however clinical outcomes thus far have been unsatisfactory. A more complete understanding of vaccinia virus gene functions must therefore precede the effective design of a next-generation vaccinia virus-based oncolytic candidate. With this downstream goal, we sought to (1) understand the unique oncolytic virus-relevant phenotypic properties of five clinical candidate vaccinia virus strains, and (2) generate and characterize a library of single-gene mutants of the Copenhagen strain of vaccinia virus. These studies resulted in the selection of vaccinia virus-Copenhagen as the wild-type strain of choice that will be utilized for future oncolytic virus development. Furthermore, the generation and initial characterization of an 89-member clonal library of vaccinia-Copenhagen single-gene mutants will be an important tool as we seek to generate a next-generation oncolytic virus candidate. Completed characterization studies challenge the role that viral thymidine kinase should play in oncolytic virus design, demonstrate novel functions of the vaccinia virus gene A47L, and provide an understanding of the role of the vaccinia virus gene F15L. These studies also raise the concept of the personalized selection of oncolytic virotherapeutics. This virus library has the potential to increase the fundamental understanding of vaccinia virus biology in this field as well as in the study of vaccine development and pathogen-host interactions.
APA, Harvard, Vancouver, ISO, and other styles
6

Bleckwenn, Nicole Aleece. "Protein production development with recombinant vaccinia virus." College Park, Md. : University of Maryland, 2004. http://hdl.handle.net/1903/1416.

Full text
Abstract:
Thesis (Ph. D.) -- University of Maryland, College Park, 2004.
Thesis research directed by: Chemical Engineering. Title from t.p. of PDF. Includes bibliographical references. Published by UMI Dissertation Services, Ann Arbor, Mich. Also available in paper.
APA, Harvard, Vancouver, ISO, and other styles
7

Gardner, Jeremy Damien. "Characterisation of the vaccinia virus gene A39R." Thesis, University of Oxford, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.365448.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Major, James R. "Interactions of dendritic cells with vaccinia virus." Thesis, University of Oxford, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.401096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Odell, Mark. "An analysis of vaccinia virus DNA ligase." Thesis, University of Oxford, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.670258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Napoli, Andrea. "Glycerophospholipid fluorescence imaging during vaccinia virus replication." Thesis, Sorbonne Paris Cité, 2019. https://theses.md.univ-paris-diderot.fr/NAPOLI_Andrea_1_va_20190415.pdf.

Full text
Abstract:
Le virus de la vaccine (VACV) est l'organisme modèle pour l'étude des Poxviridae. Son cycle de réplication dans le cytoplasme de la cellule hôte a été largement étudié par microscopie optique et microscopie électronique. Grâce à des études génétiques approfondies, le rôle de certaines des 250 protéines du virus a été élucidé. Cependant, les mécanismes d’acquisition de la membrane du virus, notamment le rôle des lipides cellulaires impliqués, restent mal connus. L’étude de la composition des membranes de VACV purifiés par spectrométrie de masse a montré qu’elles présentent un enrichissement en acide phosphatidique (PA) et en dérivés de phosphatidylinositoles (PIPs). De plus, des études in vitro ont permis d’identifier certaines protéines virales capables de se lier aux PIPs in vitro. Le rôle de ces lipides dans le cycle de vie du virus, en particulier, dans la biogenèse de ses membranes n'a pas été identifié. L'objectif de ce projet de thèse est de déterminer l’implication du PA et des PIPs dans la biogenèse des membranes virales. L’expression transitoire de protéines recombinantes contenant des domaines de liaison à ces lipides a permis de déterminer la localisation du PA et des PIPs au cours de la réplication du virus. Afin de compléter ces résultats nous avons également utilisé des anticorps reconnaissant la PI4K et le PI4P. Enfin, l’utilisation d’inhibiteurs des PI3Ks et des PI4Ks a permis d’étudier le rôle de ces kinases durant l’assemblage de la membrane virale. A l'aide de ces outils, j'ai pu montrer que la localisation de ces lipides, à l'exception du PI3P, n'est pas altérée dans les cellules infectées. De plus, aucune co-localisation n’a été observée entre ces lipides et les sites de réplication du virus. Par ailleurs, nous avons observé une co-localisation entre le PI4P et les virus enveloppés ce qui est en accord avec les études précédentes montrant que les membranes du virus mature seraient dérivées de l'appareil de Golgi. Toutefois, des inhibiteurs de la synthèse du PI3P et du PI4P n'ont pas montré d’effets sur la production des membranes virales observables par microscopie optique. En conclusion, ce travail a permis de mieux définir le rôle des lipides durant la réplication de VACV. Ces résultats mettent en lumière un rôle potentiel du PI4P au cours de l’acquisition de l’enveloppe du virus ainsi qu’un rôle PI3P et de protéines reconnaissant spécifiquement le PI3P au cours des phases tardives de la réplication
Vaccinia Virus (VACV) is the model organism for the study of the Poxviridae. Its cytoplasmic life cycle has been studied extensively by light- and electron microscopy. Thanks to a robust genetic system the role of some of its 250 proteins is beginning to be understood. Nevertheless, the acquisition of its membranes is still a matter of debate, in particular the role of cellular lipids. Lipid mass spectrometry of purified VACV previously showed an enrichment of phosphatidic acid (PA) and phosphatidylinositol derivatives (PIPs) in the viral membrane. Although some viral proteins have been shown to bind PIPs in vitro the role of these lipids in the viral life cycle, in particular viral membrane biogenesis, remains elusive.The aim of this work is to determine whether PA and PIPs are relocated in infected cells to the site of viral membrane biogenesis. For both PA and PIPs, I used recombinant proteins containing PA or PIP binding domains fused to eGFP, expressed them by transient transfection to follow their localization during viral replication. In addition, I used antibodies for the recognition of PI4K and PI4P. In order to understand the biochemical role of PIPs, I used pan-PI3K and PI4K inhibitors to study their effect on viral assembly. Using these tools, I could show that the lipids under investigation did not display an altered localization, with the exception of PI3P which showed a different pattern in infected cells. None of the PIPs analyzed co-localized with the sites of primary VACV membrane biogenesis. Consistent with the fact that the mature virus acquires additional membranes derived from the Golgi complex, I could show a co-localization of wrapped virus with PI4P, known to localize to this cellular organelle. However, drugs inhibiting PI3P and PI4P biosynthesis did not show any effect on VACV membrane biogenesis, at least at the light microscopy level. In conclusion, this work sharper defines the role of lipids during VACV replication. In particular, it opens the way to further studies on the putative role of PI4P during wrapping and the fate of PI3P and PI3P binding proteins during late replication
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Vaccinia virus"

1

Mercer, Jason, ed. Vaccinia Virus. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9593-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Isaacs, Stuart N., ed. Vaccinia Virus and Poxvirology. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1385/1592597890.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Isaacs, Stuart N., ed. Vaccinia Virus and Poxvirology. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-876-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bennett, Alice Marie. Co-expression of vaccine antigens in vaccinia virus. Manchester: University of Manchester, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Neal, Isaacs Stuart, ed. Vaccinia virus and poxvirology: Methods and protocols. Totowa, N.J: Humana Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Carroll, Miles William. Expression analysis and immunogenicity of human immunodeficiency virus type 1 envelopeglycoprotein in vaccinia virus. Manchester: University of Manchester, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Xu, Fan. Construction of vaccinia virus recombinants carrying fragments of the rotavirus gene encoding VP7. [s.l.]: typescript, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schneider, Henriette. Rescue of measles virus using the vaccinia vector MVA-T7 & analysis of recombinant measles viruses mutated in the RNA editing site. [s.l.]: [s.n.], 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ferran, Maureen C., and Gary R. Skuse, eds. Recombinant Virus Vaccines. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6869-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

1919-, Fukai Kōnosuke, and Japan Intractable Diseases Research Foundation., eds. Virus vaccines in Asian countries. [Tokyo]: University of Tokyo Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Vaccinia virus"

1

Smith, G. L. "Recombinant vaccinia virus vaccines." In Recent Developments in Prophylactic Immunization, 313–33. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bartlett, D. L. "Vaccinia Virus." In Monographs in Virology, 130–59. Basel: KARGER, 2001. http://dx.doi.org/10.1159/000061723.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shida, Hisatoshi. "Vaccinia Virus Hemagglutinin." In Subcellular Biochemistry, 405–40. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4899-1675-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moss, Bernard. "Vaccinia virus vectors." In Biotechnology for Solving Agricultural Problems, 317–23. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4396-4_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moss, B. "Vaccinia Virus Vectors: Applications to Vaccines." In Progress in Immunology, 1131–36. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83755-5_151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Smith, Geoffrey L., and Alain Vanderplasschen. "Extracellular Enveloped Vaccinia Virus." In Advances in Experimental Medicine and Biology, 395–414. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5331-1_51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chalikonda, Sricharan, and David L. Bartlett. "Vaccinia and Pox-Virus." In Gene Therapy for Cancer, 73–85. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-222-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moss, Bernard. "Vaccinia Virus Expression Vectors." In Progress in Vaccinology, 415–21. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3508-8_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rooney, James F., Charles R. Wohlenberg, and Abner Louis Notkins. "Vaccinia Virus Recombinants as Potential Herpes Simplex Virus Vaccines." In Genetically Engineered Vaccines, 183–89. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Isaacs, Stuart N. "Working Safely with Vaccinia Virus." In Vaccinia Virus and Poxvirology, 1–13. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1385/1-59259-789-0:001.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccinia virus"

1

Protsenko, M. A., E. I. Filippova, E. V. Makarevich, I. A. Gorbunova, T. V. Teplyakova, and N. A. Mazurkova. "ANTIVIRAL PROPERTIES OF EXTRACTS OF BASIDIOMYCETES OF THE NOVOSIBIRSK REGION." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-259.

Full text
Abstract:
Dry ethanolic and aqueous extracts from fruiting bodies and cultivated mycelium of basidiomycetes were obtained and investigated for chemical composition. In vitro extracts are active against influenza virus A, herpes simplex virus type 2, vaccinia virus and mouse poxvirus. The in vivo antiviral activity of Fomes fomentarius mycelium extract against influenza virus subtype H3N2 was studied.
APA, Harvard, Vancouver, ISO, and other styles
2

Raafat, Nermin, Chantal Mengus, Michael Heberer, Giulio C. Spagnoli, and Paul Zajac. "Abstract 1500: Modulation of recombinant vaccinia virus vector immunogenicity." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Weiyi, Peihong Dai, Ning Yang, Stewart Shuman, Taha Merghoub, Jedd D. Wolchok, and Liang Deng. "Abstract A007: Intratumoral delivery of inactivated vaccinia virus is more efficacious than live oncolytic vaccinia virus in murine bilateral tumor implantation models." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-a007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ramachandran, Mohanraj, and Magnus Essand. "Abstract B181: Adenovirus, Semliki Forest virus and vaccinia virus-induced immunogenic cell death augments oncolytic virus immunotherapy." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-b181.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Trella, Emanuele. "Abstract A016: Multipotency of a CD40L-expressing recombinant vaccinia virus." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-a016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Konyakhina, Yu V., A. A. Sergeev, K. A. Titova, S. A. Pyankov, S. N. Yakubitskiy, and S. N. Shchelkunov. "LOW-DOSE SMALLPOX VACCINATION IN A MOUSE MODEL." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-254.

Full text
Abstract:
Vaccinia virus (VACV) strains caused a more pronounced production of antibodies with intradermal (i.d.) injection compared to scarification (s.s.) inoculation. To test for developed protective immunity at 62 day post vaccination (dpv), mice were intranasally infected with a cowpox virus. The results showed that i.d. injection provided the development of protective immunity in mice to a much greater extent compared to s.s. inoculation with VACV strains.
APA, Harvard, Vancouver, ISO, and other styles
7

Shulgina, I. S., S. N. Yakubitskiy, A. A. Sergeev, K. A. Titova, M. B. Borgoyakova, E. V. Starostina, L. I. Karpenko, and S. N. Shchelkunov. "EFFECT OF THE ATI GENE DELETION ON PATHOGENICITY AND IMMUNOGENICITY OF THE VACCINIA VIRUS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-268.

Full text
Abstract:
Among nonvirion proteins of the vaccinia virus (VACV), a 94-kDa protein (a truncated form of ATI protein) is synthesized in the largest quantity. This protein is a major immunogen upon infection of humans and animals with VACV. Meanwhile, antibodies specific to this protein are not virus-neutralizing. The present study aimed to investigate the effect of production of this protein on manifestation of pathogenicity and immunogenicity of VACV in a mouse model.
APA, Harvard, Vancouver, ISO, and other styles
8

Kim, Jee Hung, Woo Sun Kwon, Tae Soo Kim, Kyu Hyun Park, Joong Bae Ahn, Namhee Lee, Ji Won Choi, Hyun Cheol Chung, and Sun Young Rha. "Abstract B132: Antitumor effect of oncolytic vaccinia virus in gastric cancer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1535-7163.targ-17-b132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Panopoulos, Evangelos, Emanuele Trella, Nermin Raafat, Chantal Mengus, Giulio Spagnoli, and Paul Zajac. "Abstract 2843: Recombinant Vaccinia virus expressing CD40L: a multipotent antitumor immunogenic reagent." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2843.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

TIMIRYASOVA, TATYANA M., YONG A. YU, SHAHROKH SHABAHANG, ISTVAN FODOR, and ALADAR A. SZALAY. "VISUALIZATION OF VACCINIA VIRUS INFECTION USING THE RENILLA-LUCIFERASE-GFP FUSION PROTEIN." In Proceedings of the 11th International Symposium. WORLD SCIENTIFIC, 2001. http://dx.doi.org/10.1142/9789812811158_0111.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccinia virus"

1

Buckley, Patricia E., Kevin P. O'Connell, and Gary D. Ouellette. Review of Vaccinia Virus and Baculovirus Viability Versus Virucides. Fort Belvoir, VA: Defense Technical Information Center, March 2008. http://dx.doi.org/10.21236/ada480422.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schurig, Gerhardt G. Expression of Brucella Antigens in Vaccinia Virus to Prevent Brucellosis in Humans: Protection Studies in Mice. Fort Belvoir, VA: Defense Technical Information Center, August 2000. http://dx.doi.org/10.21236/ada382850.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gates, Sean Damien. Biophysical analysis of bacterial and viral systems. A shock tube study of bio-aerosols and a correlated AFM/nanosims investigation of vaccinia virus. Office of Scientific and Technical Information (OSTI), May 2013. http://dx.doi.org/10.2172/1108845.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Butler, Nadia, and Soha Karam. Evidence Review: COVID-19 Vaccine Acceptance by Key Influencers in the MENA Region - Teachers and Healthworkers. Institute of Development Studies (IDS), November 2021. http://dx.doi.org/10.19088/sshap.2021.039.

Full text
Abstract:
As COVID-19 vaccines have been deployed and scaled, concerns about vaccine acceptance have emerged. Effective management of the virus requires that communities everywhere buy into the public health measures designed to protect them, including vaccines. Low acceptance presents a serious challenge for achieving sufficient coverage to reduce circulation of the virus and the risk of new variants emerging. Surveys conducted early in the pandemic showed that the Middle East region had one of the lowest COVID-19 vaccine acceptance rates globally. The low acceptance is driven by specific factors in the region and its different countries and populations; these factors need to be taken into account when formulating policy, programmes and interventions. This review synthesises evidence on vaccine acceptance among two key groups in the Middle East and North Africa (MENA) region: teachers and health workers. It draws from academic studies most of which were cross-sectional studies, largely conducted between February 2020 and June 2021, and grey literature reports, including social listening reports. This review is intended to inform strategies for risk communications and community engagement (RCCE) relating to COVID-19 vaccine uptake, with the aim of boosting confidence in and acceptance of the vaccines among these groups across the region. It is part of the Social Science in Humanitarian Action Platform (SSHAP) series on social science considerations relating to COVID-19 vaccines and was developed for SSHAP by Anthrologica (Nadia Butler and Soha Karam) at the request of the UNICEF MENA Regional Office. It was reviewed by Rose Aynsley (WHO) Amaya Gillespie (UNICEF) and Olivia Tulloch (Anthrologica). The evidence review is the responsibility of SSHAP.
APA, Harvard, Vancouver, ISO, and other styles
5

Geisbert, Thomas W., and Peter B. Jahrling. Towards a Vaccine Against Ebola Virus. Fort Belvoir, VA: Defense Technical Information Center, January 2003. http://dx.doi.org/10.21236/ada428607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Konakanchi, Lakshmi sravya. Vaccine Development for Respiratory Syncytial Virus. Ames (Iowa): Iowa State University, January 2020. http://dx.doi.org/10.31274/cc-20240624-1577.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vakharia, Vikram, Shoshana Arad, Yonathan Zohar, Yacob Weinstein, Shamila Yusuff, and Arun Ammayappan. Development of Fish Edible Vaccines on the Yeast and Redmicroalgae Platforms. United States Department of Agriculture, February 2013. http://dx.doi.org/10.32747/2013.7699839.bard.

Full text
Abstract:
Betanodaviruses are causative agents of viral nervous necrosis (VNN), a devastating disease of cultured marine fish worldwide. Betanodavirus (BTN) genome is composed of two single-stranded, positive-sense RNA molecules. The larger genomic segment, RNA1 (3.1 kb), encodes the RNA-dependent RNA polymerase, while the smaller genomic segment, RNA 2 (1.4kb), encodes the coat protein. This structural protein is the host-protective antigen of VNN which assembles to form virus-like particles (VLPs). BTNs are classified into four genotypes, designated red-spotted grouper nervous necrosis virus (RGNNV), barfin flounder nervous necrosis virus (BFNNV), tiger puffer nervous necrosis virus (TPNNV), and striped jack nervous necrosis virus (SJNNV), based on phylogenetic analysis of the coat protein sequences. RGNNV type is quite important as it has a broad host-range, infecting warm-water fish species. At present, there is no commercial vaccine available to prevent VNN in fish. The general goal of this research was to develop oral fish vaccines in yeast and red microalgae (Porphyridium sp.) against the RGNNV genotype. To achieve this, we planned to clone and sequence the coat protein gene of RGNNV, express the coat protein gene of RGNNV in yeast and red microalgae and evaluate the immune response in fish fed with recombinantVLPs antigens produced in yeast and algae. The collaboration between the Israeli group and the US group, having wide experience in red microalgae biochemistry, molecular genetics and large-scale cultivation, and the development of viral vaccines and eukaryotic protein expression systems, respectively, was synergistic to produce a vaccine for fish that would be cost-effective and efficacious against the betanodavirus infection.
APA, Harvard, Vancouver, ISO, and other styles
8

Heaton, Madeline. Review of Respiratory Syncytial Virus Vaccine Developments. Ames (Iowa): Iowa State University, May 2022. http://dx.doi.org/10.31274/cc-20240624-1234.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lublin, A., H. Ly, E. Porter, S. Mor, Y. Farnoushi, and S. M. Goyal. Novel vaccination strategies to combat chicken arthritis/tenosynovitis reoviruses in US and Israel. Israel: United States-Israel Binational Agricultural Research and Development Fund, 2020. http://dx.doi.org/10.32747/2020.8134154.bard.

Full text
Abstract:
Objectives: The general objective of the research was to study the evolution of lameness/tendon rupture-associated CARVs (chicken avian reovirus) in the US and Israel with a view to develop novel vaccines for its control. -- Specific aims: 1. To perform comparative genomic analysis and phylodynamics of CARV strains from the US and Israel, to determine space-time distribution of variant viruses; to propose unified criteria for assigning them to genotypes and genotype constellations, to determine re-assortments and rate of substitutions in the re-emerging viruses, and to identify specific strains suitable to be used for a safe and effective vaccine for the control of multiple contemporary CARV strains. 2. To develop a live virus vectored bivalent vaccine and a bivalent subunit vaccine against new CARV strains in US and Israel.
APA, Harvard, Vancouver, ISO, and other styles
10

Trent, Dennis W. Development of a Genetically Engineered Venezuelan Equine Encephalitis Virus Vaccine. Fort Belvoir, VA: Defense Technical Information Center, April 1991. http://dx.doi.org/10.21236/ada237590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Vaccinia virus' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography